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A definitive conclusion regarding the value of low-dose extended duration adjuvant interferon-alpha therapy in the treatment of
malignant melanoma is only possible once data on health-related quality of life (HRQoL) and costs have been considered. This trial
randomised 674 patients to interferon alpha-2a (3 megaunits three times per week for 2 years or until recurrence) or placebo.
Health-related quality of life (QoL) was to be assessed up to 60 months using the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30. Data for the economic analysis, including cost information and the EQ-5D were also
collected. Patients in the observation (OBS) group had significantly better mean follow-up quality of on five dimensions of the
EORTC QLQ-C30 functional scales: role functioning (P¼ 0.033), emotional functioning (P¼ 0.003), cognitive functioning
(P¼ 0.001), social functioning (P¼ 0.003) and global health status (P¼ 0.001). Patients in the OBS group had significantly better
mean follow-up symptom scores on seven dimensions of the EORTC QLQ-C30 V1 symptom scales. Economic data showed that
costs were d3066 higher in the interferon group and produces an incremental cost per quality-adjusted life year of d41 432 at 5 years.
The results show that interferon has significant effects on QoL and symptomatology and is unlikely to be cost-effective in this patient
group in the UK.
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The role of interferon-alpha in malignant melanoma has long been
the debated and researched, with over 6000 patients entered into
trials (Molife and Hancock, 2002). One aspect of this has been the
effectiveness of low-dose extended duration adjuvant therapy. A
recent study in 674 patients with thick primary cutaneous
melanoma showed no significant difference in overall survival
or recurrence-free survival up to 5 years (Hancock et al, 2004).
This, together with other trial evidence (Ascierto et al, 2006),
points to there being no routine role for low-dose therapy within
this patient group.
A definitive conclusion is not possible, however, until data on
health-related quality of life (HRQoL) and costs have been
considered alongside the survival data. It is possible that a HRQoL
advantage exists, or that the cost differentials are such that the
treatment may be considered cost-effective even in the face of
nonsignificant clinical findings.
Data from within AIM-High have been reported on toxicity and
change in Karnofsky Performance Status (Hancock et al, 2004), but
these data offer only a partial view of HRQoL. This paper reports
on the HRQoL data from AIM-High plus cost and cost-
effectiveness as estimated by an incremental cost per quality-
adjusted life year (QALY).
MATERIALS AND METHODS
Patients within the study were randomised to either interferon
alpha-2a at 3 megaunits three times per week for 2 years or until
recurrence, or placebo. The study protocol was approved by the
relevant research ethics committee and all participating patients
gave informed written consent.
HRQoL data in the form of the European Organisation for
Research and Treatment of Cancer (EORTC) QLQ-C30 were
originally intended to be collected at baseline, 3, 6, 12, 24, 36, 48
and 60 months for a subgroup of patients. However, HRQoL data
were actually collected at a variety of time points postrandomisa-
tion from 3 days to 77 months. Data for the economic analysis,
including cost information and the EQ-5D were collected at 3, 6,
12, 24, 36, 48 and 60 months. These economic data were only
collected for a subgroup of patients, selected as every fifth patient
to enter the study.
The European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 is a 30-item cancer-specific instrument
designed to assess the health-related quality of life (QoL) of cancer
patients participating in international clinical trials (Aaronson
et al, 1993). The QLQ-C30 version 1.0 used in the AIM-High Trial
incorporated five functional scales: physical (PF), role (RF),
cognitive (CF), emotional (EF) and social (SF); three symptom
scales: fatigue (FA), pain (PA), nausea and vomiting (NV); a global
health status/QoL scale (QL) and six single items assessing
additional symptoms commonly reported by cancer patients:
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dyspnoea (DY), loss of appetite (AP), insomnia (SL), constipation
(CO), diarrhoea (DI) and a single item on the perceived financial
impact of the disease (FI). All of the scales and single-item
measures range in score from 0 to 100. A high scale score
represents a higher response level. Thus a high score for a
functional scale represents a high/healthy level of functioning; a
high score for the global health status/QoL represents a high QoL;
but a high score for a symptom scale/item represents a high level
of symptomatology/problems.
Patient utilities were obtained from the EQ-5D questionnaire.
The EQ-5D is a five-dimensional health state classification. The
five dimensions are mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. These five dimensions are each
assessed by a single question on a three point ordinal scale (no
problems, some problems, extreme problems). An EQ-5D ‘health
state’ is defined by selecting one level from each dimension. A total
of 243 health states are thus defined. Values or preference weights
for a sample of these health states were obtained from a general
community sample using a Time-Trade-Off (TTO) technique.
Estimates for all health states were extrapolated from this sample
by statistical regression modelling. The EQ-5D preference-based
measure can be regarded as a continuous outcome scored on
a 0.59 to 1.00 scale, with 1.00 indicating ‘full health’ and
0 representing dead. The negative EQ-5D scores represent certain
health states valued as worse than dead.
Data on resource use covered all key areas of care; interferon
dose, inpatient and outpatient hospital care, community nurse and
general practitioner care. Data on interferon were collected via the
study case report form as completed by the study clinician or
research nurse. The other economic data, including the EQ-5D,
were collected through a patient completed questionnaire.
Analysis
Data for the EORTC QLQ-C30 were scored using the EORTC
Scoring Manual (Fayers et al, 1995). EQ-5D data were scored using
UK population values (Dolan, 1997), and combined with mortality
data to calculated QALYs (Drummond et al, 1997). As baseline EQ-
5D values were missing for baseline, these were imputed from a
regression of EORTC QLQ-C30 responses on EQ-5D values from
other visits.
Differences in patient characteristics between groups were tested
for using independent sample t-tests, or w2 tests, as appropriate.
The Kaplan –Meier method was used to calculate the time from
randomisation to death, and the log rank test to compare the
survival times of both groups (Altman, 1991). HRQoL data were
collected at a variety of time points postrandomisation from 3 days
to 2136 days, mean 403 days. Patients had between 1 and 13 follow-
up QoL assessments, with an average of 3.85 assessments
postrandomisation. Given this variation in data collection we
decided on a relatively straightforward approach to the analysis of
the longitudinal data which involved the use of summary measures
(Matthews et al, 1990). We summarised follow-up QoL responses
for each individual subject by taking the simple average of their
follow-up QoL responses over time as our summary measure
(Matthews et al, 1990) as we were concerned with differences in
overall levels of QoL rather than more subtle effects.
Differences in mean follow-up HRQoL between the groups were
compared using a multiple linear regression model, with mean
follow-up HRQoL as the outcome variable and baseline HRQoL,
overall survival status (dead or censored) and treatment group as
covariates. P-values of less than 0.05 were regarded as being
statistically significant.
The economic analysis followed guidelines set down by the
National Institute for Clinical Excellence (2004). Costs were
calculated by combining resource use data with unit costs
representing national estimates (British Medical Association,
2002; Netten and Curtis, 2003). Costs beyond 1 year were
discounted at 3.5% per annum. Prices are at 2003/4 levels with
prices adjusted using the Hosptial and Community Health Services
Pay and Price Index where appropriate (Netten and Curtis, 2003).
Cost differences were tested for using independent sample t-tests.
Randomised (N=674) 
Observation 
(n=336)
Interferon alpha 
(n=338)
Baseline assessments 
Quality of life (QoL) 230 (68%) 
Cost    60 (18%) 
Cost and QoL   43 (13%) 
Baseline assessments 
Quality of life (QoL) 214 (64%) 
Cost    51 (15%) 
Cost and QoL   39 (12%) 
Analysed  
QoL n=211 (68%) 
Cost n=60 
Analysed  
QoL n=187 (56%) 
Cost n= 51 
Follow-up  
Quality of life  211 (62) 
Mortality  338 (100%) 
Cost  60 (18%) 
Cost and QoL 42 (12%) 
Follow-up  
Quality of life  187 (56%) 
Mortality  336 (100%) 
Cost   51 (15%) 
Cost and QoL 37 (11%) 
Figure 1 Enrolment, treatment and follow-up of study patients.
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An incremental cost-effectiveness ratio was calculated using mean
costs and QALYs.
Economic data can be severely limited by missing data as both
the costs and the QALYs are cumulative measures (i.e. totals over
the entire follow-up period). Consequently, if only one value is
missing from the full series of follow-up data, the total cannot
be calculated. To avoid this problem, missing data imputa-
tion becomes an important part of analysing economic data.
Within this study, the last observation carried forward was used to
impute missing data in order to calculate total costs and QALYs
(Heyting et al, 1992).
RESULTS
Health-related QoL
Figure 1 shows that 444 patients (out of 674) or 66% had a
valid baseline QoL assessment; 230/338 (68%) in the IFN group
Table 1 Comparison of samples analysed
Economic sample (n¼ 111) HRQoL sample (n¼ 444) HRQoL follow-up sample (n¼ 398) Full sample (n¼ 674)
n % n % n % n %
Overall survival status
Censored 58 52.3 202 45.5 186 46.7 323 47.9
Died 53 47.7 242 54.5 212 53.3 351 52.1
Total 111 100.0 444 100.0 398 100.0 674 100.0
Gender
Female 42 37.8 186 41.9 166 41.7 292 43.3
Male 69 62.2 258 58.1 232 58.3 382 56.7
Total 111 100.0 444 100.0 398 100.0 674 100.0
Stage
L 6 5.4 41 9.2 35 8.8 74 11.0
LM 23 20.7 89 20.0 77 19.3 130 19.3
RMD 16 14.4 53 11.9 46 11.6 85 12.6
RMR 66 59.5 261 58.8 240 60.3 385 57.1
Total 111 100.0 444 100.0 398 100.0 674 100.0
Age
Mean 51.59 51.6 51.4 52.0
(s.d.) 13.29 12.9 12.7 13.1
L¼ localised; LM¼ locally metastatic; RMD¼ regionally metastatic at diagnosis; RMR¼ regionally metastatic at recurrence.
Table 2 Baseline clinical characteristics and QoL in control and intervention (n¼ 398)
Group randomised to
Interferon Observation
n Mean s.d. n Mean s.d.
Patient characteristics
Age (years) 211 50.6 (12.6) 187 52.3 (12.8)
Time (days) between entry to study and first QoL assessment 211 1.1 (2.8) 187 1.0 (1.6)
Time (days) between first and last QoL assessment 211 392.2 (353.3) 187 417.0 (342.3)
No. of valid follow-up QoL assessments 211 3.8 (2.3) 187 3.9 (2.4)
EORTC QLQ-C30 function domains
Physical functioning 211 88.7 (19.8) 187 89.0 (19.4)
Role functioning 210 83.1 (29.5) 187 84.2 (27.0)
Emotional functioning 211 79.1 (20.7) 187 79.7 (21.1)
Cognitive functioning 211 89.5 (19.1) 187 91.4 (15.8)
Social functioning 211 80.2 (26.3) 187 82.0 (25.3)
Global health status/Qol 211 71.4 (20.9) 187 73.8 (19.3)
EORTC QLQ-C30 symptom scores
Fatigue 211 21.7 (23.3) 187 18.5 (21.3)
Nausea and vomiting 211 2.4 (6.9) 187 2.0 (8.6)
Pain 211 19.8 (25.3) 187 14.0 (20.7)
Dyspnoea 211 5.1 (12.4) 187 6.6 (15.4)
Insomnia 211 21.6 (25.8) 187 20.1 (29.6)
Appetite loss 210 4.6 (14.8) 187 4.8 (15.3)
Constipation 211 6.5 (17.7) 187 5.2 (14.8)
Diarrhoea 211 3.6 (12.7) 187 3.6 (10.9)
Financial difficulties 211 15.0 (27.2) 187 14.3 (28.7)
For the EORTC QLQ-C30 v1 function scales a higher score represents a better level of functioning. For the EORTC QLQ-C30 v1 symptom scales a higher score represents a
worse level of symptoms.
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and 214/336 (64%) in the OBS group (P¼ 0.233). Comparison of
the n¼ 398 patients with a valid baseline QoL assessment and at
least one valid follow-up QoL assessment and n¼ 276 patients with
no baseline or follow-up QoL assessments, suggested that the two
groups have similar age (P¼ 0.151), gender (P¼ 0.349), histology
(P¼ 0.078), and lengths of follow-up (P¼ 0.528) (Table 1).
There was no interaction between treatment group and follow-
up QoL assessment status with regard to overall survival
(P¼ 0.251) and no evidence of a difference in overall survival
between the no follow-up QoL data and valid follow-up data
groups (log rank P¼ 0.84). Median survival was 4.05 years for
patients with no valid follow-up QoL data vs 3.81 years for patients
with valid baseline and follow-up QoL data. This implies we can
assume that the QoL sample of 388 patients is a randomly selected
subsample of the AIM-High trial population.
The IFN and OBS groups in the QoL sample had similar age,
gender, stage and overall mortality. The IFN and OBS groups in the
QoL sample had similar baseline EORTC QLQ-C30 scores, except
for the PAIN dimension, where the IFN had significantly higher
levels of pain, þ 5.8 (95% CI: þ 1.2 to þ 10.4, P¼ 0.013), see
Table 2. There was no evidence of a difference in overall survival
between the IFN and OBS groups (log rank P¼ 0.15) in the QoL
sample. Median survival for IFN was 4.29 years vs 3.21 years for the
OBS group (see Figure 2).
Patients in the observation (OBS) group had significantly better
mean follow-up QoL on five dimensions of the EORTC QLQ-C30
V1 functional scales: RF, EF, CF, SF and QL (see Table 3) after
adjustment for baseline QoL and overall survival status (dead or
censored). Patients in the OBS group had significantly lower
(better) mean follow-up QoL symptom scores on seven dimensions
of the EORTC QLQ-C30 V1 symptom scales: FA, NV, DY, AP, CO,
DI and FI (see Table 4) after adjustment for baseline QoL and
overall survival status (dead or censored).
Economic evaluation
In total, 134 patients were entered into the economic study and
data were available for 111 of these patients. Costs were higher for
the interferon (IFN) group in the first 2 years, then slightly lower,
thereafter. Overall, costs were d3066 higher in the IFN group. This
is almost entirely due to the cost of therapy (Figure 3), but is not
statistically significant (P¼ 0.396). The IFN group generates 0.074
more QALYs (Table 5), which is equivalent to an extra 27 days in
full health, although this is not statistically significant (P¼ 0.752).
The incremental cost per QALY for interferon therapy is
d41 432. There is considerable statistical uncertainty around this
estimate, and a threshold of d30 000 per QALY, there is only a 45%
chance of interferon being cost-effective.
DISCUSSION
These results show that HRQoL is worse in the IFN group in terms
of both functioning and symptomatology. As assessed by the
EORTC QLQ-C30, statistically significant differences were found
in terms of role functioning, emotional functioning, cognitive
functioning, social functioning and global health status.
Symptom scores in the IFN group were significantly worse for
fatigue, nausea/vomiting, dyspnoea, appetite loss, constipation
and diarrhoea.
Despite the great interest in interferon therapy for melanoma
and its recognised toxicities (Hancock et al, 2000), there are very
few large scale studies that have used validated HRQoL instru-
ments. Paterson looked at 21 patients receiving high-dose
interferon alpha-2b using the Functional Assessment of Cancer
Therapy – Biological Response Modifier (FACT-BRM) scale,
showing decreased QoL (Paterson et al, 2005). In an associated
study, Trask looked at 16 patients in a longitudinal analysis which
showed reductions in QoL (Trask et al, 2004). Bender assessed QoL
as part of a trial with 16 patients, and showed a significant
reduction in physical well-being associated with high-dose
interferon alpha-2b therapy using the Functional Assessment of
Cancer Therapy – General (FACT-G) scale (Bender et al, 2000).
The largest available study that used a validated QoL measure is
by Rataj et al (2005) that reported a study of 110 melanoma
patients receiving interferon alpha-2b patients following radical
0.0 2.0 4.0 6.0 8.0
Overall survival (years from randomisation) 
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Treatment group
Interferon mortality sample (n=338)
Interferon QoL sample (n=211)
Observation mortality sample (n=336)
Observation QoL sample (n=187)
Interferon mortality sample (n=169)
censored
Interferon QoL sample (n=108) censored
Observation mortality sample (n=154)
censored
Observation QoL sample (n=78) censored
Figure 2 Kaplan–Meier plot of overall survival by treatment group HRQoL follow-up sample.
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surgery. Using the EORTC QLQ-C30 (version 2.0) they found
treatment had an impact on physical function, social life,
emotional functioning and cognitive functioning. Direct compar-
isons of that study with this, are not possible due to limited
reporting in their paper.
Other work has been undertaken looking at QoL in melanoma
patients receiving interferon; however, this has been undertaken
with a completely different approach. Kilbridge et al (2001), for
instance, used the standard gamble technique to value a series of
health states describing the QOL associated with interferon
toxicity, melanoma recurrence and disease-free health. Their
study, based on 107 patient interviews, showed that the side
effects from interferon treatment reduced QoL, from 0.96 for the
disease-free health state to 0.81 from severe side effects.
The Kilbridge utility estimates have been combined with
mortality data from the ECOG 1684 trial (n¼ 280) to produce a
quality-adjusted survival analysis (Kilbridge et al, 2002) and a
cost-utility analysis (Crott et al, 2004). Other analyses have used
other utility estimates to describe treatment and post treatment
QoL for interferon patients (Cole et al, 1996; Hillner et al, 1997;
Lafuma et al, 2001); however, the utility figures were assigned by
the researchers rather than derived from patients.
All of these utility-based studies show that a decrease in QoL
during interferon treatment is more than offset by improved QoL
owing to reduced recurrence and reduced mortality. Consequently,
when these utility estimates are combined with the ECOG 1684
data, results tend to show that treatment with high-dose interferon
is cost-effective compared to other technologies (Hillner et al,
1997; Lafuma et al, 2001; Crott et al, 2004). These results are in
contrast to this study, which shows that while median survival is
around 1-year longer, combining QoL with mortality proves the
IFN group to be only marginally better (0.074 QALYs, P¼ 0.752).
This produces an incremental cost-effectiveness ratio of d41 432
per QALY. Using a funding threshold of d30 000 per QALY which
is at the higher end of a range used within the United Kingdom
(National Institute for Clinical Excellence, 2004), these results
show that low-dose extended duration interferon therapy is
unlikely to be considered cost-effective.
There are several reasons for these differences. Firstly, AIM-
High is a study of low dose interferon therapy, whereas ECOG 1684
is a study of high-dose therapy. Consequently, QoL, survival and
recurrence might be expected to differ. Secondly, the utility figures
are derived in completely different ways. Our study used a generic
preference based outcome measure (EQ-5D) to gather data
prospectively from within the trial, from which general population
utilities values were applied from a standard algorithm. Kilbridge
et al (2001) generated utility values from melanoma patients by
asking them to value health states describing various treatment
scenarios. Thirdly, our study estimates cost-effectiveness at
5 years, while the modelling studies look at longer time scales;
35 years in one case (Crott et al, 2004). This is an important
difference as shorter time frames generate higher incremental cost-
effectiveness ratios. While extrapolation of our results is possible,
the lower final year QALY estimate (Table 5) implies that even
worse cost-effectiveness results may be produced, if such an
analysis were undertaken.
We should also consider the deficiencies associated with our
study. Only 66% of patients in the trial had a baseline EORTC
QLQ-C30 assessment. Despite this, there appears to be no
systematic difference between patients included in our QoL
analysis, and those excluded. Another problem was that the
number and timing of QoL assessments completed, varied. This
led us to undertake a simple analysis, using a summary measure of
QoL based on the average scores. As assessments were more
frequent during interferon treatment in order to capture the
impact of side effects, the results will be weighted toward the early
months of treatment. However, repeating the analysis with average
follow-up over the first 2 years as the outcome, rather than the
total follow-up gave almost identical results to the longer follow-up
(data not shown).
Table 3 Baseline and follow-up EORTC-QLQ-C30 v1 function scores by group (n¼ 398)
Baseline Follow-up
Adjusted difference
Group n Mean s.d. Mean s.d. Difference (95% CI) P-value
Physical functioning
IFN 211 88.7 (19.8) 85.9 (20.2) 2.2 2.1 0.144
OBS 187 89.0 (19.4) 88.1 (16.8) (0.7 to 4.5)
Role functioning
IFN 210 83.1 (29.5) 80.8 (26.2) 5.1 4.3 0.033
OBS 187 84.2 (27.0) 85.6 (22.1) (0.4–8.3)
Emotional functioning
IFN 210 79.0 (20.7) 79.4 (19.0) 4.7 4.5 0.003
OBS 187 79.7 (21.1) 84.1 (17.5) (1.6–7.4)
Cognitive functioning
IFN 211 89.5 (19.1) 87.3 (16.6) 5.1 4.1 0.001
OBS 187 91.4 (15.8) 92.5 (12.6) (1.8–6.4)
Social functioning
IFN 210 80.1 (26.4) 84.9 (19.3) 5.0 4.4 0.003
OBS 187 82.0 (25.3) 89.9 (17.0) (1.5–7.3)
Global health status/Qol
IFN 210 71.6 (20.8) 67.5 (19.2) 7.2 5.9 0.001
OBS 187 73.8 (19.3) 74.7 (16.5) (3.1–8.7)
For the EORTC QLQ-C30 v1 function scales a higher score represents a better level of functioning. The treatment group difference in mean follow-up scores is adjusted for
baseline score and overall survival status (dead or censored). A positive follow-up difference implies the observation (OBS) group has a better level of functioning at follow-up,
than the interferon (IFN) group.
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We followed the advice of Cox et al (1992) for QoL studies which
recommended simplicity of design, analysis and presentation of
QoL assessments. Therefore, we decided to use a simple approach
and not the simultaneous assessment of QoL and survival. There
are several approaches to the simultaneous assessment of QoL and
survival including: QALYs (for which we employed the EQ-5D),
Q-TWiST (quality-adjusted time with spent with symptoms of
disease and toxicity of treatment) and multistate survival analysis
(Billingham et al, 1999). The latter two approaches would require
the definition of a finite number of health states in terms of the 15
EORTC QLC-30 dimension scores. We felt it was very difficult to
define a set of finite, mutually exclusive and exhaustive health
states that are clinically meaningful and fully describe the
experiences of patients with malignant melanoma using the 15
dimensions of the EORTC QLC-30.
We assumed that the missing QoL data are missing at random
and that dropout was noninformative. We found that the dropout
rates and survival experience were similar across the treatment
arms and believe that the between-treatment comparisons of QoL
remain unbiased. We also included a term for overall survival
status in our regression model to adjust for whether the patient
was alive or dead during follow-up. This term should take into
account that patients who died during follow-up may have a
different average QoL at follow-up than patients who were alive or
censored.
Further loss of data was present when the economic results are
considered, such that data on only 111 patients were available for
analysis. Even for these patients, missing data meant that
imputation was required to produce a rectangular data set. While
differences between this economic subsample and the full sample
are not statistically significant, we are limited in our ability to
detect differences between the two arms due to the smaller sample
size. This problem is perhaps compounded by the possible
insensitivity of the EQ-5D seen in several studies (Harper et al,
1997; Nicholl et al, 2001; Patel et al, 2004). Taken together, the lack
of a clear pattern in the QALY estimates shown in Table 5 is
difficult to interpret.
Table 4 Baseline and mean follow-up EORTC-QLQ-C30 v1 Symptom
scores by group (n¼ 398)
Baseline Follow-up
Follow-up
Adjusted
difference
n Mean s.d. Mean s.d. Difference (95% CI) P-value
Fatigue
IFN 211 21.7 (23.3) 29.0 (21.7) 10.8 9.1 0.001
OBS 187 18.5 (21.3) 18.2 (17.7) (12.1 to 6.1)
Nausea and
vomiting
IFN 211 2.4 (6.9) 6.1 (10.8) 3.4 3.4 0.001
OBS 187 2.0 (8.6) 2.7 (8.6) (5.3 to 1.6)
Pain
IFN 211 19.8 (25.3) 16.8 (21.1) 2.7 0.1 0.937
OBS 187 14.0 (20.7) 14.0 (18.2) (3.4 to 3.1)
Dyspnoea
IFN 211 5.1 (12.4) 12.2 (16.2) 2.7 3.7 0.010
OBS 187 6.6 (15.4) 9.5 (16.8) (6.5 to 0.9)
Insomnia
IFN 211 21.6 (25.8) 23.1 (23.6) 3.8 3.2 0.123
OBS 187 20.1 (29.6) 19.4 (23.4) (7.2 to 0.9)
Appetite loss
IFN 210 4.6 (14.8) 12.4 (20.8) 5.8 6.2 0.001
OBS 187 4.8 (15.3) 6.6 (15.1) (9.5 to 3.0)
Constipation
IFN 211 6.5 (17.7) 7.9 (16.6) 3.7 3.3 0.011
OBS 187 5.2 (14.8) 4.1 (10.8) (5.8 to 0.7)
Diarrhoea
IFN 211 3.6 (12.7) 8.8 (13.6) 4.5 4.4 0.001
OBS 187 3.6 (10.9) 4.3 (11.8) (6.9 to 2.0)
Financial
difficulties
IFN 210 15.1 (27.3) 11.8 (23.6) 4.8 4.7 0.001
OBS 187 14.3 (28.7) 7.0 (15.6) (7.4 to 2.0)
For the EORTC QLQ-C30 v1 symptom scales a higher score represents a worse
level of symptoms. The treatment group difference in mean follow-up scores is
adjusted for baseline score and overall survival status (dead or censored). A negative
follow-up difference implies the observation (OBS) group has a lower/better level of
symptoms, at follow-up, than the interferon (IFN) group.
Table 5 Profile of quality-adjusted life years for interferon and control patients
Mean QALYs (s.d.)
Year 1 Year 2 Year 3 Year 4 Year 5 Total
Observation group (n¼ 51) 0.79 (0.18) 0.62 (0.27) 0.43 (0.37) 0.29 (0.35) 0.19 (0.31) 2.33 (1.25)
Interferon group (n¼ 60) 0.76 (0.22) 0.67 (0.29) 0.50 (0.34) 0.31 (0.35) 0.16 (0.29) 2.40 (1.19)
Quality-adjusted life years are calculated by multiplying quality of life by length of life, such that 1 year in full health is equivalent to one quality-adjusted life year (QALY). When 1
year produces less than one QALY, this reflects less than full health, for example, 0.5 QALYs is 1 year in a health state valued at 0.5, which is deemed to be equivalent to 6
months (0.5 years) in full health.
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Figure 3 Total costs over 5 years within the two groups (n¼ 111).
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Looking beyond this study, it is difficult to cast light on other
QoL evidence and economic evaluations, as methods are different,
as too are the interferon dosing regimens. However, given that
such a clear picture of QoL is produced with the EORTC QLQ-C30
we would recommend its use for further studies of interferon
treatment. The much cited ECOG 1684 study did not incorporate
prospective QoL assessment, and so subsequent evaluations have
had to add on supplementary studies. While several improvements
to future economic evaluations have been suggested (Crott, 2004),
basing future evaluations on trial-based QoL and/or utility
estimates would appear to be important given the differences
identified here.
Few studies have assessed the impact of interferon therapy
on health related QoL using validated instruments. These results
show that interferon has significant effects on QoL and sympto-
matology. Our associated economic analysis also showed that
overall, adjuvant low-dose extended duration interferon therapy
does not appear cost-effective in this patient group in the
UK context.
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